bubble image


The Arcutis team has unmatched expertise in dermatology, inflammation and immunology, and has collectively developed or commercialized more than 50 FDA-approved products.


President and CEO

Chief Technical Officer

Chief Financial Officer

Chief Commercial Officer

General Counsel

Senior Vice President, Operations

Vice President, Investor Relations and Corporate Communications

Vice President, Clinical Development

Vice President, Finance

Vice President, Quality

Vice President, Clinical Operations

Vice President, Market Access

Vice President, Marketing

Vice President, Regulatory Affairs

Vice President, Biometrics

Vice President, Medical Affairs

Vice President, Commercial Strategy and Operations

Board of Directors

Scientific Advisors

Strategic Collaborations

Arcutis and AstraZeneca have entered into a licensing agreement for exclusive worldwide rights to all topical dermatological uses of roflumilast.

In December 2019, Arcutis exercised its option under a 2018 License Agreement with Jiangsu Hengrui Medicine Co., Ltd. of China (Hengrui) for an exclusive license to the active pharmaceutical ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), for all topical dermatological uses in the United States, Canada, Europe and Japan. Arcutis plans to develop ARQ-252 for hand eczema and other inflammatory dermatoses.